TORONTO, April 18, 2019 (GLOBE NEWSWIRE) -- Platinex Inc. (CSE: PTX) announces assignment of its ownership rights, under an option agreement with Skead Holdings Ltd and Ashley Gold Mines Limited respecting a 50% interest in claim L4212960, to Goldeye Explorations Ltd., a subsidiary of Trea...Read More
TORONTO, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Platinex Inc. (CSE: PTX) announces the resignations of Mr. Walter Henry as President, CEO and director and Mr. Tom Hussey as director with immediate effect. Mr. James R. Trusler, Chairman and director of the Company has assumed the role of interim CEO.&#...Read More
TORONTO, Jan. 25, 2019 (GLOBE NEWSWIRE) -- Platinex Inc. (CSE: PTX) announces execution of a shares-for-debt settlement transaction of an option payment on claims optioned from Skead Holdings Ltd. and Ashley Gold Mines Ltd. in which Platinex will issue 600,000 common shares at a price of $0.05 pe...Read More
TORONTO, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Platinex Inc. (CSE:PTX) ("Platinex" or the "Company") announces that Carmelo Marrelli will be stepping into the role as CFO due to internal changes at the Marrelli Support Services office. Cindy Davis, former CFO will still rema...Read More
TORONTO, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Platinex Inc. (CSE:PTX) (“Platinex” or the "Company") announces the appointment of Robert Blake as Co-CEO and Director, subject to standard regulatory approvals. Following the Company’s press release August 2, 2018, wher...Read More
TORONTO, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Platinex Inc. (CSE:PTX) ("Platinex" or the "Company") wishes to provide an update on various activities that the Company has been pursuing. Oregon Projects Update As announced in the press release in January 31, 2018, the Company h...Read More
TORONTO, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Platinex Inc. (CSE:PTX) (“Platinex” or the "Company") announces that Mr. Bruce Reilly and Mr. Mark Scarrow have resigned as officers and directors of the Company. President and CEO of Platinex, Walter Henry, stated “A...Read More
TORONTO, May 16, 2018 (GLOBE NEWSWIRE) -- Platinex Inc. (CSE:PTX) (the "Company" or "Platinex"), announces the appointment of current Director Walter Henry as the Company’s new Chief Executive Officer effective May 15, 2018. Mr. Henry succeeds James Trusler, who will re...Read More
TORONTO, April 04, 2018 (GLOBE NEWSWIRE) -- Platinex Inc. (CSE:PTX) (the "Company" or "Platinex") is pleased to announce that the Company has signed a letter of intent (“LOI”) to acquire a 51% interest in Glas Huis Inc. (“Glas Huis”), an awar...Read More
MORRISTOWN, N.J., March 27, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that it expects to resume distribution of the 20 mg dosage strength of Zohydro® ER (hydrocodone bitartrate) with BeadTek® on March...Read More
TORONTO, March 21, 2018 (GLOBE NEWSWIRE) -- Platinex Inc. (CSE:PTX) (the "Company" or "Platinex") announces that the Company’s investee, Intergalactic Foods, LLC (“IGF”), has received a processing license from the Oregon Liquor Control Commission...Read More
TORONTO, March 13, 2018 (GLOBE NEWSWIRE) -- Platinex Inc. (CSE:PTX) (the "Company" or “Platinex") announced today that it has changed its auditor from Mahendra CA Professional Corporation ("Former Auditor") to UHY McGovern Hurley LLP ("Successor Audit...Read More
TORONTO, March 13, 2018 (GLOBE NEWSWIRE) -- Platinex Inc. (CSE:PTX) announces execution of a shares-for-debt settlement transaction of cumulative overdue advance royalty payments in which Platinex will issue 292,307 common shares at a price of $0.13 per share to Skead Holdings Ltd., in connect...Read More
MORRISTOWN, N.J., March 08, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today financial results for the three and twelve months ended December 31, 2017. Fourth Quarter 2017 Financial Highlights Fourth quarter net re...Read More
MORRISTOWN, N.J., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that the Company will report financial results for the fourth quarter and fiscal year ended December 31, 2017, after the market close on Thur...Read More
MORRISTOWN, N.J., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced the launch of an authorized generic version of Treximet® (sumatriptan/naproxen sodium) in the U.S. by the Company’s subsidiary, M...Read More
Director John R. Leone Named as the Company’s Lead Independent DirectorAngus Smith Promoted to Senior Vice President, Chief Business Officer and Principal Financial Officer MORRISTOWN, N.J., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty...Read More
MORRISTOWN, N.J., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that it has entered into a settlement agreement with Actavis Laboratories FL (“Actavis”) resolving patent litigation related to...Read More
Anticipated Cost Savings of $7-$8 Million MORRISTOWN, N.J., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that, due to the impending loss of exclusivity of TREXIMET® (sumatriptan and naproxen sodium...Read More
MORRISTOWN, N.J., Nov.16, 2017(GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced the election of two new directors to its Board, John R. Leone and Douglas J. Swirsky at P...Read More